Biotech Values

[DewDiligence]

XOMA reports 2Q13 results; no change in cash-usage guidance

http://finance.yahoo.com/news/xoma-highlights-recent-achievements-reports-200100500.html

On June 30, 2013, XOMA had cash and cash equivalents of $57.9 million… The Company reconfirmed its anticipated cash used in ongoing operating activities during 2013 will be approximately $50 million, primarily reflecting the costs associated with conducting clinical and preclinical activities. This guidance initially was provided on March 12, 2013.

CC at 4:30pm ET.